Overview
- The FDA is moving to let compounding pharmacies, which mix custom medicines for individual patients, make about 14 peptides that were restricted in 2023, the New York Times reported Tuesday.
- Health Secretary Robert F. Kennedy Jr. had pledged on Joe Rogan’s podcast to remove 14 peptides from the restricted list, casting the change as a way to boost access.
- Senior FDA officials have reservations and fear the move could look political rather than evidence-based, according to the Times’ reporting echoed by Ars Technica.
- Experts say there are no randomized trials showing these peptides work and warn about risks that include dosing errors, contamination from gray-market supply, growth stimulation that could spur cancers, and recent critical illnesses after Las Vegas conference injections; the FDA has also cited possible deaths tied to GHRP‑2.
- The final list is not public, though outlets expect popular candidates like BPC‑157 and growth‑hormone‑releasing agents such as CJC‑1295 and Ipamorelin, a shift that could draw some buyers to regulated pharmacies yet fuel wider use and risky peptide “stacks.”